Allergy Therapeutics PLC - Sussex, England-based biotechnology company - Expects revenue to rise by 1.1%, or by 4% at constant currency, to £34.0 million in the six months ended December from £33.6 million a year ago. Sales are expected to continue to grow in the second half of the financial year. Overall, expects sales for the full year ending June 30 to exceed sales in the corresponding period ended June 2024. Reports cash position of £21.7 million at the end of December, rising from £12.9 million a year ago, following receipt of new £20 million five-year term loan. Chief Executive Manuel Llobet says: ‘We enter 2025 building strong momentum across all aspects of our business. Our return to first-half growth and strengthened position, having secured the Hayfin facility in late 2024, give us the confidence and financial stability to further our ambitious strategy.’
Current stock price: 6.65 pence, down 7.6% in London on Tuesday
12-month change: more than trebled
Copyright 2025 Alliance News Ltd. All Rights Reserved.
